RT Journal Article
T1 Immunohistochemistry-based taxonomical classification of Bladder cancer predicts response to neoadjuvant chemotherapy
A1 Font, Albert
A1 Domènech, Montserrat
A1 Raquel Benítez, Raquel
A1 Rava, Marta
A1 Marqués, Miriam
A1 Ramírez, José L.
A1 Pineda Sanjuan, Silvia
A1 Domínguez Rodríguez, Sara
A1 Gago, José L.
A1 Badal, Josep
A1 Carrato, Cristina
A1 López, Héctor
A1 Quer, Ariadna
A1 Castellano Gauna, Daniel Ernesto
A1 Malats, Núria
A1 Real, Francisco X.
A2 Mok, Samuel C.
AB Background: Platinum-based neoadjuvant chemotherapy (NAC) increases the survival of patients with organ-confined urothelial bladder cancer (UBC). In retrospective studies, patients with basal/squamous (BASQ)-like tumors present with more advanced disease and have worse prognosis. Transcriptomics-defined tumor subtypes are associated with response to NAC. Aim: To investigate whether immunohistochemical (IHC) subtyping predicts NAC response. Methods: Patients with muscle-invasive UBC having received platinum-based NAC were identified. Tissue microarrays were used to type tumors for KRT5/6, KRT14, GATA3, and FOXA1. Outcomes: progression-free survival and disease-specific survival; univariable and multivariate Cox regression models were applied. Results: We found a very high concordance between mRNA and protein expression. Using IHC-based hierarchical clustering, we classified 126 tumors in three subgroups: BASQ-like (FOXA1/GATA3 low; KRT5/6/14 high), Luminal-like (FOXA1/GATA3 high; KRT5/6/14 low), and mixed-cluster (FOXA1/GATA3 high; KRT5/6 high; KRT14 low). Applying multivariable analyses, patients with BASQ-like tumors were more likely to achieve a pathological response to NAC (OR 3.96; p = 0.017). The clinical benefit appeared reflected in the lack of significant survival differences between patients with BASQ-like and luminal tumors. Conclusions: Patients with BASQ-like tumors—identified through simple and robust IHC—have a higher likelihood of undergoing a pathological complete response to NAC. Prospective validation is required.
PB MDPI
SN 2072-6694
YR 2020
FD 2020-07-03
LK https://hdl.handle.net/20.500.14352/96685
UL https://hdl.handle.net/20.500.14352/96685
LA eng
NO Font A, Domènech M, Benítez R, Rava M, Marqués M, Ramírez JL, et al. Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy. Cancers 2020;12:1784. https://doi.org/10.3390/cancers12071784.
NO Asociación Española Contra el Cáncer
NO Fondo de Investigaciones Sanitarias (España)
NO Instituto de Salud Carlos III (España)
NO Red Temática de Investigación Cooperativa en Cáncer (España)
DS Docta Complutense
RD 23 dic 2025